GRAHAM CORP
For the period ended Mar 31, 2026. Filed Jun 8, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Jun 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
As of March 31, 2026, we conducted our business from the following locations.
| Location | Products/Operations | Square Footage | Owned or Leased |
|---|---|---|---|
| Batavia, NY | Corporate Headquarters | 43,000 | Owned |
| Batavia, NY | Manufacturing, Warehousing and R&D | 300,000 | Owned |
| Arvada, CO | Office | 18,000 | Leased |
| Arvada, CO | Manufacturing and Warehousing | 83,000 | Leased |
| Greenville, SC | Office and Warehousing | 12,000 | Leased |
| Houston, TX | Sales Office | 1,500 | Leased |
| Indiantown, FL | Cryogenic Test Facility | 8,800 | Owned |
| Jupiter, FL | Manufacturing and R&D | 16,900 | Leased |
| Louisville, CO | Manufacturing and Office | 24,000 | Leased |
| Suzhou, China | Sales and Engineering | 4,900 | Leased |
| Ahmedabad, India | Sales and Engineering | 800 | Leased |
| Pune, India | Sales and Engineering | 2,200 | Leased |
We believe that our properties are generally in good condition, are well maintained, and are suitable and adequate to carry on our business. However, in order to support our future growth, we have initiated the following capital projects:
During fiscal 2024, we received a $13,500 strategic investment from a major Defense customer to expand and enhance our Batavia, NY production capabilities. This expansion included the construction of a new 30,000 square foot manufacturing facility on our existing campus and the purchase of production and automated welding equipment to be used in the facility. This facility was completed in fiscal 2026.
During fiscal 2025, we purchased a plot of land adjacent to the BN campus in order to support organic growth. We intend to construct an additional 30,000 square foot manufacturing facility on that site in fiscal 2027.
During fiscal 2025, we purchased land and began construction of a cryogenic (liquid hydrogen, oxygen, methane) testing facility near our P3 subsidiary. This facility enhances our capabilities and allows us to provide quality assurance testing for our customers. This facility was completed in fiscal 2026.
During fiscal 2025, we received a $2,200 strategic investment from a major Defense customer to support the implementation of new Radiographic Testing (“RT”) equipment at our Batavia, NY facility. We contributed an additional $1,400 towards this project for a total project cost of $3,600. This expansion is expected to be completed in the first quarter of fiscal 2027.
We believe we will be able to construct these facilities on commercially reasonable terms. We expect to spend between 7% to 10% of revenue on capital expenditures each year for the next several years in order to fund our future growth.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.